Xiaoni Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoni Liu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Xiangjun Chen
Department of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, National Center for Neurological Disorders, Shanghai, China
4 shared publications Bo Deng
Department of Neurology and Institute of Neurology Huashan Hospital, Fudan University Shanghai China
2 shared publicationsHai Yu
Department of Neurology and Institute of Neurology Huashan Hospital, Fudan University Shanghai China
2 shared publicationsSiqi Dong
Department of Neurology, Huashan Hospital Fudan University Shanghai People's Republic of China
2 shared publicationsWenbo Yang
Department of Neurology and Institute of Neurology Huashan Hospital, Fudan University Shanghai China
2 shared publicationsXiang Zhang
Department of Neurology and Institute of Neurology Huashan Hospital, Fudan University Shanghai China
2 shared publications
Latest Publications
- Open Access
- 7 March 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (3) , e70107
Microglial Activation Visualized by [18F]‐DPA714 PET Is a Potential Marker of Severity and Prognosis for Anti‐LGI1 Encephalitis
Background and Purpose: Whether microglial activation plays an important role in the pathogenesis of autoimmune encephalitis (AE), such as anti‐leucine‐rich, glioma‐inactivated‐1 (LGI1) encephalitis, remains unknown. [18F]‐DPA714 PET targeting the translocator protein (TSPO) is a novel method to detect neuroinflammation via visualizing activated microglia. In this study, we aimed to investigate the application of [18F]‐DPA714 PET in anti‐LGI1 encephalitis.Methods: Patients with anti‐LGI1 encephalitis and non‐inflammatory controls (NIC) underwent [18F]‐DPA714 PET scans were enrolled. Standardized uptake value ratios normalized to the cerebellum (SUVRc) in LGI1‐AE patients were calculated for semi‐quantitative analysis. The microglial activation marker, soluble triggering receptor expressed on myeloid cells 2 (sTREM2) was measured in cerebrospinal fluid (CSF) to demonstrate its correlation with [18F]‐DPA714 PET imaging. Logistic regression analysis was used to identify potential predictors of prognosis.Results: Forty‐six patients with anti‐LGI1 encephalitis were included in this study. Increased TSPO uptake was identified in the hippocampus, frontal cortex, and caudate nucleus. Montreal Cognitive Assessment (MoCA) score was significantly correlated with SUVRc in the hippocampus (R2 = 0.13, p = 0.034) and frontal cortex (R2 = 0.13, p = 0.017). Overexpressed sTREM2 in CSF was correlated with SUVRc in the hippocampus (R2 = 0.18, p = 0.04). SUVRc in the hippocampus significantly decreased after immunotherapy and was associated with improvement of MoCA score (R2 = 0.54, p = 0.023). Increased SUVRc in the frontal cortex and hippocampus was associated with unfavorable disability recovery (odds ratio [OR] = 7.1, 95% CI 1.67–29.9, p = 0.008) and persistent amnesia (OR = 5.4, 95% CI 1.3–22.2, p = 0.021) respectively.Conclusion: Microglial activation visualized by [18F]‐DPA714 PET is associated with clinical features and may be used as a potential biomarker for therapeutic and prognostic evaluation.
- 7 March 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (3) , e70107
Open AccessMicroglial Activation Visualized by [18F]‐DPA714 PET Is a Potential Marker of Severity and Prognosis for Anti‐LGI1 Encephalitis
Background and Purpose: Whether microglial activation plays an important role in the pathogenesis of autoimmune encephalitis (AE), such as anti‐leucine‐rich, glioma‐inactivated‐1 (LGI1) encephalitis, remains unknown. [18F]‐DPA714 PET targeting the translocator protein (TSPO) is a novel method to detect neuroinflammation via visualizing activated microglia. In this study, we aimed to investigate the application of [18F]‐DPA714 PET in anti‐LGI1 encephalitis.Methods: Patients with anti‐LGI1 encephalitis and non‐inflammatory controls (NIC) underwent [18F]‐DPA714 PET scans were enrolled. Standardized uptake value ratios normalized to the cerebellum (SUVRc) in LGI1‐AE patients were calculated for semi‐quantitative analysis. The microglial activation marker, soluble triggering receptor expressed on myeloid cells 2 (sTREM2) was measured in cerebrospinal fluid (CSF) to demonstrate its correlation with [18F]‐DPA714 PET imaging. Logistic regression analysis was used to identify potential predictors of prognosis.Results: Forty‐six patients with anti‐LGI1 encephalitis were included in this study. Increased TSPO uptake was identified in the hippocampus, frontal cortex, and caudate nucleus. Montreal Cognitive Assessment (MoCA) score was significantly correlated with SUVRc in the hippocampus (R2 = 0.13, p = 0.034) and frontal cortex (R2 = 0.13, p = 0.017). Overexpressed sTREM2 in CSF was correlated with SUVRc in the hippocampus (R2 = 0.18, p = 0.04). SUVRc in the hippocampus significantly decreased after immunotherapy and was associated with improvement of MoCA score (R2 = 0.54, p = 0.023). Increased SUVRc in the frontal cortex and hippocampus was associated with unfavorable disability recovery (odds ratio [OR] = 7.1, 95% CI 1.67–29.9, p = 0.008) and persistent amnesia (OR = 5.4, 95% CI 1.3–22.2, p = 0.021) respectively.Conclusion: Microglial activation visualized by [18F]‐DPA714 PET is associated with clinical features and may be used as a potential biomarker for therapeutic and prognostic evaluation.
- Open Access
- 26 January 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (1) , e70256
Prognostic Value of Cerebrospinal Fluid and Serum Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Correlation Study
Background: The diagnostic and prognostic values of serum neurofilament light chain (sNfL), in comparison to cerebrospinal fluid (CSF) neurofilament light chain (cNfL), and other clinical parameters in amyotrophic lateral sclerosis (ALS) at the time of diagnosis remain elusive.Methods: We examine paired serum and CSF samples from 80 ALS patients and 21 control subjects, all obtained at the time of diagnosis. Additional serum samples were collected from 51 other ALS patients. NfL concentrations were quantified using the single molecule array (Simoa) technique.Results: Our findings demonstrate a robust correlation between NfL levels in matched CSF and serum samples. Notably, both sNfL (p < 0.0001) and cNfL (p < 0.0001) exhibited significantly elevated levels in ALS patients compared to controls. Furthermore, baseline sNfL concentrations, as well as cNfL levels, emerged as predictive indicators of subsequent disease progression rate (sNfL: p < 0.0001, cNfL: p = 0.0005) and overall survival (sNfL: p = 0.0073, cNfL: p = 0.0044). Employing a Cox regression model, we identified baseline sNfL level (HR = 1.01, p = 0.013), and diagnostic delay (HR = 0.94, p = 0.003) as independent prognostic factors for mortality. Furthermore, we constructed a nomogram model that incorporates both sNfL and pertinent clinical variables, which substantially enhances the accuracy of predicting disease outcomes (Concordance Index, 0.808).Conclusion: Our study underscores the robust correlation between sNfL and cNfL in ALS patients and establishes baseline sNfL as a potent and independent prognostic marker for mortality.
- 26 January 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (1) , e70256
Open AccessPrognostic Value of Cerebrospinal Fluid and Serum Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Correlation Study
Background: The diagnostic and prognostic values of serum neurofilament light chain (sNfL), in comparison to cerebrospinal fluid (CSF) neurofilament light chain (cNfL), and other clinical parameters in amyotrophic lateral sclerosis (ALS) at the time of diagnosis remain elusive.Methods: We examine paired serum and CSF samples from 80 ALS patients and 21 control subjects, all obtained at the time of diagnosis. Additional serum samples were collected from 51 other ALS patients. NfL concentrations were quantified using the single molecule array (Simoa) technique.Results: Our findings demonstrate a robust correlation between NfL levels in matched CSF and serum samples. Notably, both sNfL (p < 0.0001) and cNfL (p < 0.0001) exhibited significantly elevated levels in ALS patients compared to controls. Furthermore, baseline sNfL concentrations, as well as cNfL levels, emerged as predictive indicators of subsequent disease progression rate (sNfL: p < 0.0001, cNfL: p = 0.0005) and overall survival (sNfL: p = 0.0073, cNfL: p = 0.0044). Employing a Cox regression model, we identified baseline sNfL level (HR = 1.01, p = 0.013), and diagnostic delay (HR = 0.94, p = 0.003) as independent prognostic factors for mortality. Furthermore, we constructed a nomogram model that incorporates both sNfL and pertinent clinical variables, which substantially enhances the accuracy of predicting disease outcomes (Concordance Index, 0.808).Conclusion: Our study underscores the robust correlation between sNfL and cNfL in ALS patients and establishes baseline sNfL as a potent and independent prognostic marker for mortality.
- 12 February 2023
- Published by Springer Nature in Phenomics
- Vol. 3 (2) , 167-181
Presence of Rare Variants is Associated with Poorer Survival in Chinese Patients with Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with phenotypic and genetic heterogeneity. Recent studies have suggested an oligogenic basis of ALS, in which the co-occurrence of two or more genetic variants has additive or synergistic deleterious effects. To assess the contribution of possible oligogenic inheritance, we profiled a panel of 43 relevant genes in 57 sporadic ALS (sALS) patients and eight familial ALS (fALS) patients from five pedigrees in east China. We filtered rare variants using the combination of the Exome Aggregation Consortium, the 1000 Genomes and the HuaBiao Project. We analyzed patients with multiple rare variants in 43 known ALS causative genes and the genotype–phenotype correlation. Overall, we detected 30 rare variants in 16 different genes and found that 16 of the sALS patients and all the fALS patients examined harbored at least one variant in the investigated genes, among which two sALS and four fALS patients harbored two or more variants. Of note, the sALS patients with one or more variants in ALS genes had worse survival than the patients with no variants. Typically, in one fALS pedigree with three variants, the family member with three variants (Superoxide dismutase 1 (SOD1) p.V48A, Optineurin (OPTN) p.A433V and TANK binding kinase 1 (TBK1) p.R573H) exhibited much more severe disease phenotype than the member carrying one variant (TBK1 p.R573H). Our findings suggest that rare variants could exert a negative prognostic effect, thereby supporting the oligogenic inheritance of ALS.
- 12 February 2023
- Published by Springer Nature in Phenomics
- Vol. 3 (2) , 167-181
Presence of Rare Variants is Associated with Poorer Survival in Chinese Patients with Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with phenotypic and genetic heterogeneity. Recent studies have suggested an oligogenic basis of ALS, in which the co-occurrence of two or more genetic variants has additive or synergistic deleterious effects. To assess the contribution of possible oligogenic inheritance, we profiled a panel of 43 relevant genes in 57 sporadic ALS (sALS) patients and eight familial ALS (fALS) patients from five pedigrees in east China. We filtered rare variants using the combination of the Exome Aggregation Consortium, the 1000 Genomes and the HuaBiao Project. We analyzed patients with multiple rare variants in 43 known ALS causative genes and the genotype–phenotype correlation. Overall, we detected 30 rare variants in 16 different genes and found that 16 of the sALS patients and all the fALS patients examined harbored at least one variant in the investigated genes, among which two sALS and four fALS patients harbored two or more variants. Of note, the sALS patients with one or more variants in ALS genes had worse survival than the patients with no variants. Typically, in one fALS pedigree with three variants, the family member with three variants (Superoxide dismutase 1 (SOD1) p.V48A, Optineurin (OPTN) p.A433V and TANK binding kinase 1 (TBK1) p.R573H) exhibited much more severe disease phenotype than the member carrying one variant (TBK1 p.R573H). Our findings suggest that rare variants could exert a negative prognostic effect, thereby supporting the oligogenic inheritance of ALS.
- 1 May 2019
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 330, 81-86
Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: An observation study in Chinese patients
- 1 May 2019
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 330, 81-86
Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: An observation study in Chinese patients
- 1 September 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 511 (1) , 288-295
Bioequivalence and food effect of heat-stressed and nonheat-stressed dapagliflozin 2.5- and 10-mg tablets
- 1 September 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 511 (1) , 288-295
Bioequivalence and food effect of heat-stressed and nonheat-stressed dapagliflozin 2.5- and 10-mg tablets